Intra-Hepatic Cholangiocarcinoma Treated with GEMOX + Cetuximab Protocol
Keywords:Cholangiocarcinoma, Intrahepatic Cancer, Treatment, Case Report
AbstractNew studies show a possible benefit of combining Gemcitabine, Oxaliplatin and Cetuximab for the treatment of intrahepatic tumors. However, there is currently no consensus on this in the literature. Hence, this article contributes to the debate by presenting a case of cholangiocarcinoma(biliary tract cancer), treated with a modified Gemcitabine, Oxaliplatin and Cetuximab protocol, which evolved to a considerable regression of the tumor and a complete radiologic response assessed by PET-CT Scan. The case report is of a female adult, who presented with a cholangiocarcinoma extending to hepatic segments V and VIII which met the unresectability criteria. She was submitted to chemotherapy,consisting of a combination of Gemcitabine, Oxaliplatin and Cetuximab for a prolonged period,followed by a maintenance interval of Cetuximabmonotherapy. After the 8thÂ cycle, the patient presented better hepatic biomarker levels; after 12months of treatment, she presented a PET-CT scan showing complete radiologic response; after 15 months of treatment, an MRI scanshowed a reduced and resectable tumor. Our case report suggests use of theGemcitabine + Oxaliplatin(GEMOX) plus Cetuximab protocol as a neoadjuvant settingfor patients with unresectable cholangiocarcinoma submitted to the GEMOX protocol, presenting a progressing disease. Additionally, our case report confirms the GEMOX plus Cetuximab protocol can be modified according to clinical response so patients can obtain maximum therapeutic gain despite minor or adverse reactions.
Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with
unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010;11:1142-8.
Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. The Lancet Oncology 2014;15:819-28.
Skipworth JR, Keane MG, Pereira SP. Update on the management of cholangiocarcinoma. Digestive diseases 2014;32:570-8.
Servajean C, Gilabert M, Piana G, et al. One case of intrahepatic cholangiocarcinoma amenable to resection after radioembolization. World journal of gastroenterology : WJG 2014;20:5131-4.
Sadeghi S, Finn RS. Systemic therapy for cholangiocarcinoma. Clinical Liver Disease 2014;3:86-9.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under aÂ Creative Commons Attribution LicenseÂ that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open AccessÂ and Benefits of Publishing Open Access).